BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Ferrer Internacional 

Edifici L'illa
Diagonal, 549 5ª planta
Barcelona    E-08029  Spain
Phone: 34-93-600-3700 Fax: 34-93-490-7078


SEARCH JOBS




Industry
Medical Device






 Company News
Alexza Pharmaceuticals, Inc. (ALXA) And Ferrer Internacional Expand ADASUVE® Partnership 10/27/2014 8:27:58 AM
Alexza Pharmaceuticals, Inc. (ALXA) And Ferrer Internacional Provide Update On ADASUVE® European Commercial Activities 9/19/2014 7:21:03 AM
Ferrer Internacional Licenses Commercialisation Rights For Ozenoxacin In The United States To Medimetriks Pharmaceuticals, Inc. 3/24/2014 11:39:24 AM
Alexza Pharmaceuticals, Inc. (ALXA) And Ferrer Internacional Announce The Launch Of ADASUVE® (Inhalation Powder, Loxapine) In Romania 3/14/2014 10:31:42 AM
Ferrer Internacional To Develop Lorediplon For Insomnia With Ildong Pharmaceuticals And ErgoMed Clinical Research 2/3/2014 9:04:16 AM
Partnership Between AOP Orphan Pharmaceuticals AG and Ferrer Internacional: Joint Marketing of Adasuve® in CEE 10/29/2013 8:45:51 AM
Ferrer Internacional and Medivir AB (MVIRb.F) Enter Agreement for Commercializing a New Treatment for Agitation Associated With Schizophrenia and Bipolar Disease in the Nordics 9/18/2013 10:10:21 AM
Ferrer Internacional Successfully Completes a Phase III Clinical Trial in Adult and Paediatric Patients With Impetigo for Novel Antibacterial Compound Ozenoxacin 6/12/2013 9:11:17 AM
Grupo Ferrer Internacional S.A. Successfully Completes an Absorption, Tolerability and Safety Study in Juveniles as Young as Two Months of Age for Novel Antibacterial Compound Ozenoxacin 10/5/2012 11:00:15 AM
Ferrer Internacional Initiates Phase III Clinical Studies for Novel Antibacterial Compound, Ozenoxacin, in Development as a Topical Treatment for Impetigo and Other Infectious Dermatological Conditions 1/19/2012 10:27:03 AM
12